Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary (CUP)

Felipe Ades; Evandro de Azambuja; Gedske Daugaard; Lieveke Ameye; Camilo Moulin; Marianne Paesmans; Daphne De Jong; Lore Decoster; Jacques De Greve; Gustavo Ismael; Anne Kirstine Møller; Martine Piccart; Ahmad Awada

doi:10.1179/1973947813y.0000000085

Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary (CUP)

Felipe Ades, Evandro de Azambuja, Gedske Daugaard, Lieveke Ameye, Camilo Moulin, Marianne Paesmans, Daphne De Jong, Lore Decoster, Jacques De Greve, Gustavo Ismael, Anne Kirstine Møller, Martine Piccart, Ahmad Awada

Department of Clinical Medicine

3 Citations (Scopus)

Abstract

CupPrint® is a genomic signature able to identify 47 different cancer types. The aim of our study was to compare the accuracy of this genomic signature to that of a full clinical work-up in diagnosing the primary tumour site. Patients with newly diagnosed, untreated metastatic tumours were eligible for this trial. The clinical work-up and gene expression profiling on a biopsy from a metastatic site were started at the same time. The study was planned using a one-stage Fleming design. Patients in whom no primary site was diagnosed by the clinical work-up were excluded. Out of the 67 patients registered, the primary site was identified by clinical work-up in 36 patients, and diagnosis with CupPrint was obtained in 53. There were 31 evaluable patients with both clinical and CupPrint diagnoses, and out of these a similar diagnosis was obtained in 11 patients, i.e. the concordance rate was 35% (95% confidence interval: 19-55%). The median time to diagnosis through the clinical work-up was 48 days, and 10 days with CupPrint (P<0.001). We concluded that in patients with newly diagnosed metastatic tumours, CupPrint has low accuracy in diagnosing the primary cancer site.

Original language	English
Journal	Journal of Chemotherapy
Volume	25
Issue number	4
Pages (from-to)	239-246
Number of pages	8
ISSN	1120-009X
DOIs	https://doi.org/10.1179/1973947813y.0000000085
Publication status	Published - Aug 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1179/1973947813y.0000000085

Cite this

Ades, F., de Azambuja, E., Daugaard, G., Ameye, L., Moulin, C., Paesmans, M., De Jong, D., Decoster, L., De Greve, J., Ismael, G., Møller, A. K., Piccart, M., & Awada, A. (2013). Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary (CUP). Journal of Chemotherapy, 25(4), 239-246. https://doi.org/10.1179/1973947813y.0000000085

Ades, F, de Azambuja, E, Daugaard, G, Ameye, L, Moulin, C, Paesmans, M, De Jong, D, Decoster, L, De Greve, J, Ismael, G, Møller, AK, Piccart, M & Awada, A 2013, 'Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary (CUP)', Journal of Chemotherapy, vol. 25, no. 4, pp. 239-246. https://doi.org/10.1179/1973947813y.0000000085

@article{c2183a438c38434da34801cc8ce63677,

title = "Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary (CUP)",

abstract = "CupPrint{\textregistered} is a genomic signature able to identify 47 different cancer types. The aim of our study was to compare the accuracy of this genomic signature to that of a full clinical work-up in diagnosing the primary tumour site. Patients with newly diagnosed, untreated metastatic tumours were eligible for this trial. The clinical work-up and gene expression profiling on a biopsy from a metastatic site were started at the same time. The study was planned using a one-stage Fleming design. Patients in whom no primary site was diagnosed by the clinical work-up were excluded. Out of the 67 patients registered, the primary site was identified by clinical work-up in 36 patients, and diagnosis with CupPrint was obtained in 53. There were 31 evaluable patients with both clinical and CupPrint diagnoses, and out of these a similar diagnosis was obtained in 11 patients, i.e. the concordance rate was 35% (95% confidence interval: 19-55%). The median time to diagnosis through the clinical work-up was 48 days, and 10 days with CupPrint (P<0.001). We concluded that in patients with newly diagnosed metastatic tumours, CupPrint has low accuracy in diagnosing the primary cancer site.",

author = "Felipe Ades and {de Azambuja}, Evandro and Gedske Daugaard and Lieveke Ameye and Camilo Moulin and Marianne Paesmans and {De Jong}, Daphne and Lore Decoster and {De Greve}, Jacques and Gustavo Ismael and M{\o}ller, {Anne Kirstine} and Martine Piccart and Ahmad Awada",

year = "2013",

month = aug,

doi = "10.1179/1973947813y.0000000085",

language = "English",

volume = "25",

pages = "239--246",

journal = "Journal of Chemotherapy",

issn = "1120-009X",

publisher = "Taylor & Francis",

number = "4",

}

TY - JOUR

T1 - Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary (CUP)

AU - Ades, Felipe

AU - de Azambuja, Evandro

AU - Daugaard, Gedske

AU - Ameye, Lieveke

AU - Moulin, Camilo

AU - Paesmans, Marianne

AU - De Jong, Daphne

AU - Decoster, Lore

AU - De Greve, Jacques

AU - Ismael, Gustavo

AU - Møller, Anne Kirstine

AU - Piccart, Martine

AU - Awada, Ahmad

PY - 2013/8

Y1 - 2013/8

N2 - CupPrint® is a genomic signature able to identify 47 different cancer types. The aim of our study was to compare the accuracy of this genomic signature to that of a full clinical work-up in diagnosing the primary tumour site. Patients with newly diagnosed, untreated metastatic tumours were eligible for this trial. The clinical work-up and gene expression profiling on a biopsy from a metastatic site were started at the same time. The study was planned using a one-stage Fleming design. Patients in whom no primary site was diagnosed by the clinical work-up were excluded. Out of the 67 patients registered, the primary site was identified by clinical work-up in 36 patients, and diagnosis with CupPrint was obtained in 53. There were 31 evaluable patients with both clinical and CupPrint diagnoses, and out of these a similar diagnosis was obtained in 11 patients, i.e. the concordance rate was 35% (95% confidence interval: 19-55%). The median time to diagnosis through the clinical work-up was 48 days, and 10 days with CupPrint (P<0.001). We concluded that in patients with newly diagnosed metastatic tumours, CupPrint has low accuracy in diagnosing the primary cancer site.

AB - CupPrint® is a genomic signature able to identify 47 different cancer types. The aim of our study was to compare the accuracy of this genomic signature to that of a full clinical work-up in diagnosing the primary tumour site. Patients with newly diagnosed, untreated metastatic tumours were eligible for this trial. The clinical work-up and gene expression profiling on a biopsy from a metastatic site were started at the same time. The study was planned using a one-stage Fleming design. Patients in whom no primary site was diagnosed by the clinical work-up were excluded. Out of the 67 patients registered, the primary site was identified by clinical work-up in 36 patients, and diagnosis with CupPrint was obtained in 53. There were 31 evaluable patients with both clinical and CupPrint diagnoses, and out of these a similar diagnosis was obtained in 11 patients, i.e. the concordance rate was 35% (95% confidence interval: 19-55%). The median time to diagnosis through the clinical work-up was 48 days, and 10 days with CupPrint (P<0.001). We concluded that in patients with newly diagnosed metastatic tumours, CupPrint has low accuracy in diagnosing the primary cancer site.

U2 - 10.1179/1973947813y.0000000085

DO - 10.1179/1973947813y.0000000085

M3 - Journal article

C2 - 23906077

SN - 1120-009X

VL - 25

SP - 239

EP - 246

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

IS - 4

ER -

Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary (CUP)

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this